Navigation Links
Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Date:1/17/2013

ronic HCV, accounting for 15,000 deaths in the United States in 2007.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

*Sustained virologic response (SVR) 12 and 24 weeks following treatment completion


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
2. Boehringer Ingelheim Announces Equine Research Awards
3. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
4. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
7. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/25/2014)... 25, 2014  In today,s marketplace, launching multiple products ... - as is managing a portfolio of products in ... possible - or even preferable - to pool resources ... you combine resources and activities, and what marketing and ... are just a few of the dilemmas facing pharmaceutical ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... , SAN DIEGO, Nov. 18 Rules-Based ... biomarker alliance and services agreement with Covance Inc. (NYSE: ... with a powerful combination of biomarker technologies and services for ... will use RBM as its exclusive third-party provider of multiplexed ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: ... cycle management solutions, today announced that it will participate in the ... 1 to 2, 2009 in New York. , The "fireside chat", ... time on Tuesday, December 1, 2009. A live audio webcast ...
Cached Medicine Technology:Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:7/28/2014)... St. Jude Children’s Research Hospital has ... Defense Employer Support Freedom Award from the Employer Support of ... The award is the highest honor given by the U.S. ... serve in the National Guard and Reserve. , “We deeply ... contributions to the St. Jude mission and to our country,” ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... BEER-SHEVA, ISRAEL, July 28, 2014...Mothers who live near ... weights, according to a new study, "Green Spaces ... Occupational and Environmental Medicine . , A ... Ben-Gurion University of the Negev (BGU), evaluated nearly ... cohort in Tel Aviv, Israel to determine the ...
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... findings made possible by a test developed at University ... (CU School of Pharmacy), AURORA, Colo (July 28, 2014) ... Colorado Antiviral Pharmacology Laboratory at the CU School of ... drug called Truvada (a combination of tenofovir/emtricitabine), which is ... A study presented during the AIDS 2014 Conference and ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2
... Consumer Watchdog sent a letter to Senator ... expressing their profound disappointment that consumer advocates had ... the Massachusetts senator to formulate health care reform ... recent national polls showing the public overwhelming opposed ...
... Results To Offer New Insights on How Well Asthma ... The American Lung Association of New England (ALANE) has ... offer an online survey and corresponding report that will ... being controlled and encourage them to discuss the results ...
... ROCKVILLE, Md., Feb. 20 /PRNewswire-Asia/ -- Synutra,International, ... a leading infant formula,company in China, and ... products,for infants, children and adults, today issued ... permit numbers in a published list of ...
... eFoodSafety.com, Inc., (OTC Bulletin Board: EFSF) an emerging ... aesthetics, dermatology, environmental and nutraceutical products, outlined its ... 30, 2010 during its regularly scheduled monthly investor ... eFoodSafety.com intends to increase revenues by improving the ...
... Many people seek answers to questions of motivation and ... by Justin Honaman employs lessons learned in his career ... an effort to help others direct their energies and ... chapters of "Make It Happen" that personal branding is ...
... the world,s largest autism science and advocacy organization, is teaming up ... series "Wow! Wow! Wubbzy!" - to promote World Autism Awareness Day ... autism as a worldwide health crisis. , ... New ...
Cached Medicine News:Health News:Consumer Watchdog to U.S. Senate: Don't Leave Consumers Out of Health Reform Debate, Public Opposes Mandatory Purchases of Private Insurance & Supports Opening Medicare to Everyone 2Health News:American Lung Association of New England Launches Online Asthma Control Test 2Health News:American Lung Association of New England Launches Online Asthma Control Test 3Health News:American Lung Association of New England Launches Online Asthma Control Test 4Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 2Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 3Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 2Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 3Health News:Business Strategist Applies Corporate Experience to Self-Help: 'Make It Happen' 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 3Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 4
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: